stockrowPTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
- Revenue
- +69.6%
- EPS
- −410.0%
- Free cash flow
- +90.3%
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
Follow PTCT
Alert me
PTC Therapeutics, Inc. (PTCT) Return on assets
PTC Therapeutics, Inc.'s return on assets over the twelve months to 30 September 2026 was −3.62%, down 33.3 percentage points from fiscal 2025 (29.7%). Over the past ten years it has ranged from −48.8% (fiscal 2015) to 29.7% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 29.7% | 49.84 |
| FY2024 | −20.2% | 14.62 |
| FY2023 | −34.8% | (4.12) |
| FY2022 | −30.7% | (5.41) |
| FY2021 | −25.3% | (2.40) |
| FY2020 | −22.9% | (4.53) |
| FY2019 | −18.3% | (1.39) |
| FY2018 | −17.0% | 6.95 |
| FY2017 | −23.9% | 20.89 |
| FY2016 | −44.8% | 4.01 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| PTCT PTC Therapeutics, Inc. | −3.62% |
| MANE Veradermics Incorporated compare | −20.9% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −21.6% |
| CGON CG Oncology, Inc. compare | −25.1% |
| COGT Cogent Biosciences, Inc. compare | −68.0% |
| IMVT Immunovant, Inc. compare | −71.1% |
| KOD Kodiak Sciences Inc. compare | −94.3% |
| SRRK Scholar Rock Holding Corporation compare | −94.6% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −99.8% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on PTCT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement